title: Anti-interferon-beta neutralising activity is not entirely mediated by antibodies.
abstract: Many multiple sclerosis (MS) patients treated with interferon-beta (IFNbeta) develop anti-IFNbeta antibodies (BAbs), which can interfere with both in vitro and in vivo bioactivity of the injected cytokine. Objective of this study was to correlate these measures. Among the 256 enrolled patients, 11 (4.3%) showed a significant inhibition of the IFNbeta activity in vitro, but no measurable BAbs. As a whole, in vivo bioactivity was inhibited in 9/11 (82%) of these patients. A minority of IFNbeta treated patients have a non-antibody mediated neutralising activity, which competitively inhibits the bioactivity both in vitro and in vivo.
authors.affiliation: Centro di Riferimento Regionale Sclerosi Multipla (CReSM) & Neurobiologia Clinica, ASO S. Luigi Gonzaga, Orbassano, Torino, Italy. neurobiologia@sanluigi.piemonte.it
authors.forename: Francesca
authors.initials: F
authors.lastname: Gilli
authors.forename: Fabiana
authors.initials: F
authors.lastname: Marnetto
authors.forename: Marzia
authors.initials: M
authors.lastname: Caldano
authors.forename: Paola
authors.initials: P
authors.lastname: Valentino
authors.forename: Letizia
authors.initials: L
authors.lastname: Granieri
authors.forename: Alessia
authors.initials: A
authors.lastname: Di Sapio
authors.forename: Marco
authors.initials: M
authors.lastname: Capobianco
authors.forename: Arianna
authors.initials: A
authors.lastname: Sala
authors.forename: Simona
authors.initials: S
authors.lastname: Malucchi
authors.forename: Ludwig
authors.initials: L
authors.lastname: Kappos
authors.forename: Raija L P
authors.initials: RL
authors.lastname: Lindberg
authors.forename: Antonio
authors.initials: A
authors.lastname: Bertolotto
mesh_terms: D000906:Antibodies / Q000627:therapeutic use*; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D019204:GTP-Binding Proteins / Q000235:genetics / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D047468:Immunoprecipitation; D066298:In Vitro Techniques; D016899:Interferon-beta / Q000276:immunology* / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000276:immunology* / Q000628:therapy; D064547:Myxovirus Resistance Proteins; D009500:Neutralization Tests; D017471:Receptors, Interferon / Q000378:metabolism; D012189:Retrospective Studies
chemical_list: D000906:Antibodies; D064547:Myxovirus Resistance Proteins; D017471:Receptors, Interferon; D016899:Interferon-beta; D019204:GTP-Binding Proteins